Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001193125-21-257913
Filing Date
2021-08-27
Accepted
2021-08-26 21:39:05
Documents
51
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 6-K d206395d6k.htm   iXBRL 6-K 104145
2 EX-99.1 d206395dex991.htm   iXBRL EX-99.1 672145
3 EX-99.2 d206395dex992.htm EX-99.2 143964
9 GRAPHIC g206395g20i18.jpg GRAPHIC 177097
  Complete submission text file 0001193125-21-257913.txt   3763138

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA asnd-20210630.xsd EX-101.SCH 36072
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE asnd-20210630_cal.xml EX-101.CAL 37060
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE asnd-20210630_def.xml EX-101.DEF 101328
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE asnd-20210630_lab.xml EX-101.LAB 232399
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE asnd-20210630_pre.xml EX-101.PRE 176240
10 EXTRACTED XBRL INSTANCE DOCUMENT d206395d6k_htm.xml XML 576945
Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Filer) CIK: 0001612042 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36815 | Film No.: 211213963
SIC: 2834 Pharmaceutical Preparations